CRL Global Services Builds European Lab in UK
CRL Global Services (Kansas), an independent clinical testing laboratory operation, has concluded a deal with Quotient Bioresearch (Cambridgeshire, UK) that will see CRL Global Services establish its new European laboratory hub in the UK.
CRL Global Services has chosen to construct its own laboratory in Cambridgeshire, UK, embedded within the existing facilities of Quotient Bioresearch. It will provide a further full service laboratory arm to CRL Global Services’ existing global structure. The contract also provides for an immediate close collaboration between the companies on the development and delivery of new services, particularly in the areas of bioanalysis, biomarkers, and microbiology.
David Griffiths, PhD MBA, business development director, Quotient Bioresearch, added: “We are very pleased to be working together with CRL Global Services as they construct their new laboratory in the UK. The established capabilities of the two companies are entirely complementary. I anticipate synergies that will enable us to deliver a joint offering significantly broader than available from each party working alone.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
